Wells Fargo Upgrades Enzymotec (ENZY) to Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Enzymotec Ltd. Reports Second Quarter 2015 Results
August 12, 2015 7:30 AM EDTRevenues and Adjusted EBITDA Increased for Fourth Consecutive Quarter
Q2 Net Revenues Increased 49.5% Year-Over-Year; Q2 Net Income of $0.10 Per Diluted Share
MIGDAL HA'EMEQ, Israel, Aug. 12, 2015 (GLOBE NEWSWIRE) -- Enzymotec Ltd. (Nasdaq: ENZY), a developer, manufacturer and marketer of innovative bio-active lipid ingredients, today reported financial results for the second quarter ended June 30, 2015.
Second Quarter Financial Highlights
Second quarter net revenues (equity method) increased 49.5% to $13.4 million, compared to the same quarter last year and 18.6%, compared to the first quarter of 2015.... More